OS Therapies posts 72.7% 3-yr survival for Herlystic in osteosarcoma trial
OS Therapies released final three-year survival results from its Phase 2b trial of Herlystic in resected pulmonary metastatic osteosarcoma. Patients given Herlystic lived longer than comparable historical controls, supporting the case for earlier access pathways. Work is underway on regulatory submissions in the U.S.,